Arcadia Biosciences Inc expected to post a loss of 30 cents a share - Earnings Preview
12/05/2021 03:55
* Arcadia Biosciences Inc RKDA.OQ RKDA.O is expected to show
a rise in quarterly revenue when it reports results on May 11
(estimated) .
* The Davis, California-based company is expected to report a
176.7% increase in revenue to $855 thousand from $309 thousand a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Arcadia Biosciences Inc
is for a loss of 30 cents per share. For the same quarter last
year, the company reported earnings of 29 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 7.5%
in the last three months.
* Wall Street's median 12-month price target for Arcadia
Biosciences Inc is $6.45, about 60.1% above its last closing
price of $2.57.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 -0.41 -0.41 0.88 Beat 314.6
Sep. 30 2020 -0.54 -0.54 -0.60 Missed -10.4
Jun. 30 2020 -0.61 -0.59 -1.03 Missed -75.6
Mar. 31 2020 -0.55 -0.54 0.29 Beat 153.2
Dec. -0.61 -0.57 -0.50 Beat 13
31 2019
Sep. 30 2019 -0.76 -0.77 -2.04 Missed -164.9
Jun. 30 2019 -0.91 -0.90 0.84 Beat 192.8
Mar. 31 2019 -1.01 -0.81 -2.64 Missed -225.9
This summary was machine generated May 12 at 02:55 GMT. All
figures in US dollars unless otherwise stated